W
Wiktor Mazin
Researcher at Aarhus University Hospital
Publications - 9
Citations - 159
Wiktor Mazin is an academic researcher from Aarhus University Hospital. The author has contributed to research in topics: Gene expression profiling & Cytotoxicity. The author has an hindex of 7, co-authored 9 publications receiving 148 citations.
Papers
More filters
Journal ArticleDOI
A 71-Gene Signature of TRAIL Sensitivity in Cancer Cells
TL;DR: The elevated expression of the 71 genes was able to accurately predict TRAIL sensitivity in the NCI60 training set and two test sets consisting of a total of 95 human cancer cell lines and could be evaluated clinically for predicting tumor response to TRAIL-related therapies.
Journal ArticleDOI
Development and Validation of a Gene Expression Score That Predicts Response to Fulvestrant in Breast Cancer Patients
Steen Knudsen,Thomas Jensen,Anker Jon Hansen,Wiktor Mazin,Justin P.O. Lindemann,Irene Kuter,Naomi Laing,Elizabeth Anderson +7 more
TL;DR: It is concluded that pre-screening patients with the new gene expression predictor has the potential to identify those postmenopausal women with locally advanced, estrogen-receptor-positive breast cancer most likely to respond to fulvestrant.
Journal ArticleDOI
Independent Validation of a Model Using Cell Line Chemosensitivity to Predict Response to Therapy
TL;DR: A case study to validate predictions while treating the methods as a "black box" suggests that discovering better predictors will require both cell line data and a clinical training dataset of patient samples.
Journal ArticleDOI
Expression of MicroRNAs in the NCI-60 Cancer Cell-Lines
Santosh K. Patnaik,Jesper Dahlgaard,Wiktor Mazin,Eric Kannisto,Thomas Jensen,Steen Knudsen,Sai Yendamuri,Sai Yendamuri +7 more
TL;DR: Mutation status of the cell-lines for the TP53, PTEN and BRAF but not CDKN2A or KRAS cancer-related genes was found to be associated with changes in expression of specific microRNAs, and comparable results with different datasets were noted.
Journal ArticleDOI
Development and blind clinical validation of a microRNA based predictor of response to treatment with R-CHO(E)P in DLBCL.
Steen Knudsen,Christoffer Hother,Kirsten Grønbæk,Thomas Jensen,Anker Jon Hansen,Wiktor Mazin,Jesper Dahlgaard,Michael Boe Møller,Elizabeth Ralfkiær,Peter de Nully Brown +9 more
TL;DR: Preliminary findings warrant testing in a larger cohort of relapse patients to confirm whether the miRNA based predictor can select the optimal second line treatment and increase survival.